Biosimilars: Inverting the Innovator Development Model
This article was originally published in RPM Report
When it comes to the new biosimilar pathway, it’s the IND—not the BLA—that matters.
You may also be interested in...
FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.
An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.
In the two months since the enactment of the Generic Drug User Fee Act, FDA has announced a major recruitment from the brand sector to head its generic drug activities (Gregory Geba), approved one controversial transdermal generic (Watson’s lidocaine topical patch), and elevated the generic review activities to “Super Office” status.